Cabaletta Bio · 8 hours ago
Senior Research Associate, Analytical Development
Cabaletta Bio is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases. The Senior Research Associate, Analytical Development will support routine analytical testing and method qualification for the rese-cel clinical program, contributing to the evaluation of lentiviral vectors and CAR-T cells.
BiotechnologyHealth CareMedicalRoboticsTherapeutics
Responsibilities
Perform quality control testing to evaluate lentiviral vectors, CAR-T cells and stability samples generated by internal groups and external partners
Assist in developing analytical methods for the characterization and release of lentiviral vectors and CAR-T cells
Assist to Identify and implement opportunities for analytical method improvement and participate optimization of existing analytical methods to enhance sensitivity and efficiency
Perform method qualification studies in accordance with regulatory guidelines
Perform general lab and equipment maintenance duties
Participate in technical troubleshooting and problem investigation
Prepare, evaluate, and present data internally to cross functional teams
Prepare detailed and accurate documentation of experimental procedures, results, and conclusions
Stay current with advances in analytical techniques and industry trends
Other related duties, as assigned
Qualification
Required
Bachelor's or master's degree in biology or closely related discipline, and with 1-3 years of experience
Proficient in aseptic technique for cell culture and cell-based assays
Experience in analytic techniques, including flow cytometry, qPCR/dPCR, or ELISA etc
Flexible to support various analytical activities and to learn new techniques outside of existing field of expertise
Ability to work collaboratively in a fast-paced environment
Highly organized and strong written and verbal communication skills
Strong laboratory documentation practice with high scientific integrity
Strong team orientation and passion for continuous self-development
Preferred
Experience with quality control programs for lentiviral vector and CAR-T product preferred
Experience in the biotech industry or in a startup industrial setting is preferred
Benefits
Competitive benefits
PTO
Stock option plans
Company
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Funding
Current Stage
Public CompanyTotal Funding
$310MKey Investors
5AM Ventures
2025-06-11Post Ipo Equity· $100M
2023-05-17Post Ipo Equity· $87M
2022-12-08Post Ipo Equity· $35M
Recent News
GlobeNewswire
2026-01-12
2025-12-11
Company data provided by crunchbase